谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

149P Real-world Outcomes with First-Line Afatinib in EGFR Mutant NSCLC Adenocarcinoma: A Single Centre Experience Exploring Effects of Dose-Reduction

N. Tokaca,M. O'Brien,J. Bhosle,N. Yousaf,R. Kumar,S. Popat,D. Walder

Journal of Thoracic Oncology（2018）

引用 4|浏览30
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要